Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · October 02, 2022

Feasibility of a Novel Anti–BCMA-CAR Construct for Relapsed and Refractory Light Chain Amyloidosis

Clinical Cancer Research

 

Additional Info

Clinical Cancer Research
Feasibility of a novel academic BCMA-CART (HBI0101) for the treatment of relapsed and refractory AL amyloidosis
Clin. Cancer Res 2022 Sep 15;[EPub Ahead of Print], S Kfir-Erenfeld, N Asherie, S Grisariu, B Avni, E Zimran, M Assayag, T Dubnikov Sharon, M Pick, E Lebel, A Shaulov, YC Cohen, I Avivi, CJ Cohen, P Stepensky, ME Gatt

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading